Delucchi A, Toro L, Alzamora R, et al. - Renal transplantation (RTx) effectively improves clinical results for pediatric patients with terminal chronic kidney disease, but chronic immunosuppression with glucocorticoids (GC) decreases bone growth and mineral density, authors assessed if GC impairs bone growth by raising fibroblast growth factor 23 (FGF23) expression, which has direct impacts on bone growth plate. According to the results of this post-hoc analysis of a multicentric randomized clinical trial, GC-induced impeded bone growth was related to increased plasma FGF23 and bone FGF23 expression in prepubertal rats. Investigators found that GC treatment partially lowers longitudinal bone growth by upregulation of FGF23 and FGFR3 expression, indicating that the FGF23/Klotho/FGFR3 axis at the growth plate may be a possible therapeutic target for the management of GC-induced growth impairment in children.